Pfizer’s High-Stakes Bid for Weight-Loss Drug Maker Intensifies

The pharmaceutical industry is witnessing an intense bidding war as Pfizer competes against Danish rival Novo Nordisk for control of Metsera, a biotechnology firm specializing in GLP-1 medications for weight management. This multi-billion dollar contest represents a strategic pivot for Pfizer as it seeks to strengthen its position in the rapidly expanding obesity treatment market.

Pfizer’s ambitious takeover move comes immediately following a positive financial disclosure. On Tuesday, the company released quarterly results that surpassed market expectations and raised its full-year guidance, demonstrating underlying business resilience despite declining COVID-related revenue.

Key financial highlights include:
* Adjusted earnings per share of $0.87, substantially exceeding forecasts
* Operational growth of Read more...